Hikma Pharmaceuticals USA has announced it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey.  

Late last month (June 28, 2025), the company broke ground to expand the company’s manufacturing and R&D facility in Columbus, Ohio. 

Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance, and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines.  

Source: Hikma Pharmaceuticals